BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

New insight into transglutaminase 2 and link to neurodegenerative diseases

  • Min, Boram (Department of Systems Biology, College of Life Science and Biotechnology, Yonsei University) ;
  • Chung, Kwang Chul (Department of Systems Biology, College of Life Science and Biotechnology, Yonsei University)
  • Received : 2017.07.21
  • Published : 2018.01.31
Download PDF
⟨ Previous Next ⟩

Abstract

Formation of toxic protein aggregates is a common feature and mainly contributes to the pathogenesis of neurodegenerative diseases (NDDs), which include amyotrophic lateral sclerosis (ALS), Alzheimer's, Parkinson's, Huntington's, and prion diseases. The transglutaminase 2 (TG2) gene encodes a multifunctional enzyme, displaying four types of activity, such as transamidation, GTPase, protein disulfide isomerase, and protein kinase activities. Many studies demonstrated that the calcium-dependent transamidation activity of TG2 affects the formation of insoluble and toxic amyloid aggregates that mainly consisted of NDD-related proteins. So far, many important and NDD-related substrates of TG2 have been identified, including $amlyoid-{\beta}$, tau, ${\alpha}-synuclein$, mutant huntingtin, and ALS-linked trans-activation response (TAR) DNA-binding protein 43. Recently, the formation of toxic inclusions mediated by several TG2 substrates were efficiently inhibited by TG2 inhibitors. Therefore, the development of highly specific TG2 inhibitors would be an important tool in alleviating the progression of TG2-related brain disorders. In this review, the authors discuss recent advances in TG2 biochemistry, several mechanisms of molecular regulation and pleotropic signaling functions, and the presumed role of TG2 in the progression of many NDDs.

Keywords

References

  1. Sarkar NK, Clarke DD and Waelsch H (1957) An enzymically catalyzed incorporation of amines into proteins. Biochim Biophys Acta 25, 451-452 https://doi.org/10.1016/0006-3002(57)90512-7
  2. Grenard P, Bates MK and Aeschlimann D (2001) Evolution of transglutaminase genes: identification of a transglutaminase gene cluster on human chromosome 15q15. Structure of the gene encoding transglutaminase X and a novel gene family member, transglutaminase Z. J Biol Chem 276, 33066-33078 https://doi.org/10.1074/jbc.M102553200
  3. Mehta K (2005) Mammalian transglutaminases: a family portrait. Prog Exp Tumor Res 38, 1-18
  4. Park D, Choi SS and Ha KS (2010) Transglutaminase 2: a multi-functional protein in multiple subcellular compartments. Amino Acids 39, 619-631 https://doi.org/10.1007/s00726-010-0500-z
  5. Achyuthan KE and Greenberg CS (1987) Identification of a guanosine triphosphate-binding site on guinea pig liver transglutaminase. Role of GTP and calcium ions in modulating activity. J Biol Chem 262, 1901-1906
  6. Nakaoka H, Perez DM, Baek KJ et al (1994) Gh: a GTP-binding protein with transglutaminase activity and receptor signaling function. Science 264, 1593-1596 https://doi.org/10.1126/science.7911253
  7. Hasegawa G, Suwa M, Ichikawa Y et al (2003) A novel function of tissue-type transglutaminase: protein disulphide isomerase. Biochem J 373, 793-803 https://doi.org/10.1042/bj20021084
  8. Jones RA, Nicholas B, Mian S, Davies PJ and Griffin M (1997) Reduced expression of tissue transglutaminase in a human endothelial cell line leads to changes in cell spreading, cell adhesion and reduced polymerisation of fibronectin. J Cell Sci 110, 2461-2472
  9. Mishra S and Murphy LJ (2006) The p53 oncoprotein is a substrate for tissue transglutaminase kinase activity. Biochem Biophys Res Commun 339, 726-730 https://doi.org/10.1016/j.bbrc.2005.11.071
  10. Mishra S and Murphy LJ (2004) Tissue transglutaminase has intrinsic kinase activity: identification of transglutaminase 2 as an insulin-like growth factor-binding protein-3 kinase. J Biol Chem 279, 23863-23868 https://doi.org/10.1074/jbc.M311919200
  11. Lorand L and Graham RM (2003) Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol 4, 140-156 https://doi.org/10.1038/nrm1014
  12. Takeuchi Y, Ohashi H, Birckbichler PJ and Ikejima T (1998) Nuclear translocation of tissue type transglutaminase during sphingosine-induced cell death: a novel aspect of the enzyme with DNA hydrolytic activity. Z Naturforsch C 53, 352-358
  13. Nurminskaya MV and Belkin AM (2012) Cellular functions of tissue transglutaminase. Int Rev Cell Mol Biol 294, 1-97
  14. Esposito C and Caputo I (2005) Mammalian transglutaminases. Identification of substrates as a key to physiological function and physiopathological relevance. FEBS J 272, 615-631 https://doi.org/10.1111/j.1742-4658.2004.04476.x
  15. Lesort M, Tucholski J, Miller ML and Johnson GV (2000) Tissue transglutaminase: a possible role in neurodegenerative diseases. Prog Neurobiol 61, 439-463 https://doi.org/10.1016/S0301-0082(99)00052-0
  16. Dieterich W, Ehnis T, Bauer M et al (1997) Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 3, 797-801 https://doi.org/10.1038/nm0797-797
  17. Sollid LM, Molberg O, McAdam S and Lundin KE (1997) Autoantibodies in coeliac disease: tissue transglutaminase--guilt by association? Gut 41, 851-852 https://doi.org/10.1136/gut.41.6.851
  18. Birckbichler PJ, Orr GR, Conway E and Patterson MK (1977) Transglutaminase activity in normal and transformed cells. Cancer Res 37, 1340-1344
  19. Griffin M, Smith LL and Wynne J (1979) Changes in transglutaminase activity in an experimental model of pulmonary fibrosis induced by paraquat. Br J Exp Pathol 60, 653-661
  20. Gentile V, Davies PJ and Baldini A (1994) The human tissue transglutaminase gene maps on chromosome 20q12 by in situ fluorescence hybridization. Genomics 20, 295-297 https://doi.org/10.1006/geno.1994.1170
  21. Fesus L and Piacentini M (2002) Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci 27, 534-539 https://doi.org/10.1016/S0968-0004(02)02182-5
  22. Fraij BM and Gonzales RA (1997) Organization and structure of the human tissue transglutaminase gene. Biochim Biophys Acta 1354, 65-71 https://doi.org/10.1016/S0167-4781(97)00132-2
  23. Kiraly R, Demeny M and Fesus L (2011) Protein transamidation by transglutaminase 2 in cells: a disputed Ca2+-dependent action of a multifunctional protein. FEBS J 278, 4717-4739 https://doi.org/10.1111/j.1742-4658.2011.08345.x
  24. Shrestha R, Tatsukawa H, Shrestha R et al (2015) Molecular mechanism by which acyclic retinoid induces nuclear localization of transglutaminase 2 in human hepatocellular carcinoma cells. Cell Death Dis 6, e2002 https://doi.org/10.1038/cddis.2015.339
  25. Murthy SN, Iismaa S, Begg G, Freymann DM, Graham RM and Lorand L (2002) Conserved tryptophan in the core domain of transglutaminase is essential for catalytic activity. Proc Natl Acad Sci U S A 99, 2738-2742 https://doi.org/10.1073/pnas.052715799
  26. Lee KN, Arnold SA, Birckbichler PJ et al (1993) Sitedirected mutagenesis of human tissue transglutaminase: Cys-277 is essential for transglutaminase activity but not for GTPase activity. Biochim Biophys Acta 1202, 1-6 https://doi.org/10.1016/0167-4838(93)90055-V
  27. Yee VC, Le Trong I, Bishop PD, Pedersen LC, Stenkamp RE and Teller DC (1996) Structure and function studies of factor XIIIa by x-ray crystallography. Semin Thromb Hemost 22, 377-384 https://doi.org/10.1055/s-2007-999035
  28. Pinkas DM, Strop P, Brunger AT and Khosla C (2007) Transglutaminase 2 undergoes a large conformational change upon activation. PLoS Biol 5, e327 https://doi.org/10.1371/journal.pbio.0050327
  29. Kuo TF, Tatsukawa H and Kojima S (2011) New insights into the functions and localization of nuclear transglutaminase 2. FEBS J 278, 4756-4767 https://doi.org/10.1111/j.1742-4658.2011.08409.x
  30. Milakovic T, Tucholski J, McCoy E and Johnson GV (2004) Intracellular localization and activity state of tissue transglutaminase differentially impacts cell death. J Biol Chem 279, 8715-8722 https://doi.org/10.1074/jbc.M308479200
  31. Malorni W, Farrace MG, Matarrese P et al (2009) The adenine nucleotide translocator 1 acts as a type 2 transglutaminase substrate: implications for mitochondrialdependent apoptosis. Cell Death Differ 16, 1480-1492 https://doi.org/10.1038/cdd.2009.100
  32. Stephens P, Grenard P, Aeschlimann P et al (2004) Crosslinking and G-protein functions of transglutaminase 2 contribute differentially to fibroblast wound healing responses. J Cell Sci 117, 3389-3403 https://doi.org/10.1242/jcs.01188
  33. Mhaouty-Kodja S (2004) Ghalpha/tissue transglutaminase 2: an emerging G protein in signal transduction. Biol Cell 96, 363-367 https://doi.org/10.1111/j.1768-322X.2004.tb01427.x
  34. Dupuis M, Levy A and Mhaouty-Kodja S (2004) Functional coupling of rat myometrial alpha 1-adrenergic receptors to Gh alpha/tissue transglutaminase 2 during pregnancy. J Biol Chem 279, 19257-19263 https://doi.org/10.1074/jbc.M314299200
  35. Stamnaes J, Pinkas DM, Fleckenstein B, Khosla C and Sollid LM (2010) Redox regulation of transglutaminase 2 activity. J Biol Chem 285, 25402-25409 https://doi.org/10.1074/jbc.M109.097162
  36. DiRaimondo TR, Plugis NM, Jin X and Khosla C (2013) Selective inhibition of extracellular thioredoxin by asymmetric disulfides. J Med Chem 56, 1301-1310 https://doi.org/10.1021/jm301775s
  37. Shin DM, Jeon JH, Kim CW et al (2008) TGFbeta mediates activation of transglutaminase 2 in response to oxidative stress that leads to protein aggregation. FASEB J 22, 2498-2507 https://doi.org/10.1096/fj.07-095455
  38. Begg GE, Holman SR, Stokes PH, Matthews JM, Graham RM and Iismaa SE (2006) Mutation of a critical arginine in the GTP-binding site of transglutaminase 2 disinhibits intracellular cross-linking activity. J Biol Chem 281, 12603-12609 https://doi.org/10.1074/jbc.M600146200
  39. Fabbi M, Marimpietri D, Martini S et al (1999) Tissue transglutaminase is a caspase substrate during apoptosis. Cleavage causes loss of transamidating function and is a biochemical marker of caspase 3 activation. Cell Death Differ. 6, 992-1001 https://doi.org/10.1038/sj.cdd.4400573
  40. Luciani A, Villella VR, Vasaturo A et al (2009) SUMOylation of tissue transglutaminase as link between oxidative stress and inflammation. J Immunol 183, 2775-2784 https://doi.org/10.4049/jimmunol.0900993
  41. Ku BM, Kim DS, Kim KH et al (2013) Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma. FASEB J 27, 3487-3495 https://doi.org/10.1096/fj.12-224220
  42. Min B, Park H, Lee S et al (2016) CHIP-mediated degradation of transglutaminase 2 negatively regulates tumor growth and angiogenesis in renal cancer. Oncogene 35, 3718-3728 https://doi.org/10.1038/onc.2015.439
  43. Norlund MA, Lee JM, Zainelli GM and Muma NA (1999) Elevated transglutaminase-induced bonds in PHF tau in Alzheimer's disease. Brain Res 851, 154-163 https://doi.org/10.1016/S0006-8993(99)02179-4
  44. Johnson GV, Cox TM, Lockhart JP, Zinnerman MD, Miller ML and Powers RE (1997) Transglutaminase activity is increased in Alzheimer's disease brain. Brain Res 751, 323-329 https://doi.org/10.1016/S0006-8993(96)01431-X
  45. Shinagawa R, Masuda S, Sasaki R, Ikura K and Takahata K (1997) In vitro neurotoxicity of amyloid beta-peptide cross-linked by transglutaminase. Cytotechnology 23, 77-85 https://doi.org/10.1023/A:1007999114779
  46. Curro M, Ferlazzo N, Condello S, Caccamo D and Lentile R (2010) Transglutaminase 2 silencing reduced the beta-amyloid-effects on the activation of human THP-1 cells. Amino Acids 39, 1427-1433 https://doi.org/10.1007/s00726-010-0605-4
  47. Hartley DM, Zhao C, Speier AC et al (2008) Transglutaminase induces protofibril-like amyloid beta-protein assemblies that are protease-resistant and inhibit long-term potentiation. J Biol Chem 283, 16790-16800 https://doi.org/10.1074/jbc.M802215200
  48. Boros S, Kamps B, Wunderink L, de Bruijn W, de Jong WW and Boelens WC (2004) Transglutaminase catalyzes differential crosslinking of small heat shock proteins and amyloid-beta. FEBS Lett 576, 57-62 https://doi.org/10.1016/j.febslet.2004.08.062
  49. de Jager M, van der Wildt B, Schul E et al (2013) Tissue transglutaminase colocalizes with extracellular matrix proteins in cerebral amyloid angiopathy. Neurobiol Aging 34, 1159-1169 https://doi.org/10.1016/j.neurobiolaging.2012.10.005
  50. Zhang W, Johnson BR and Bjornsson TD (1997) Pharmacologic inhibition of transglutaminase-induced cross-linking of Alzheimer's amyloid beta-peptide. Life Sci 60, 2323-2332 https://doi.org/10.1016/S0024-3205(97)00288-9
  51. Zemaitaitis MO, Lee JM, Troncoso JC and Muma NA (2000) Transglutaminase-induced cross-linking of tau proteins in progressive supranuclear palsy. J Neuropathol Exp Neurol 59, 983-989 https://doi.org/10.1093/jnen/59.11.983
  52. Tucholski J, Kuret J and Johnson GV (1999) Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination. J Neurochem 73, 1871-1880
  53. Halverson RA, Lewis J, Frausto S, Hutton M and Muma NA (2005) Tau protein is cross-linked by transglutaminase in P301L tau transgenic mice. J Neurosci 25, 1226-1233 https://doi.org/10.1523/JNEUROSCI.3263-04.2005
  54. Kalia LV and Lang AE (2015) Parkinson's disease. Lancet 386, 896-912 https://doi.org/10.1016/S0140-6736(14)61393-3
  55. Forno LS (1996) Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55, 259-272 https://doi.org/10.1097/00005072-199603000-00001
  56. Lin MK and Farrer MJ (2014) Genetics and genomics of Parkinson's disease. Genome Med 6, 48 https://doi.org/10.1186/gm566
  57. Chai C and Lim KL (2013) Genetic insights into sporadic Parkinson's disease pathogenesis. Curr Genomics 14, 486-501
  58. Beck KE, De Girolamo LA, Griffin M and Billett EE (2006) The role of tissue transglutaminase in 1-methyl-4-phenylpyridinium (MPP+)-induced toxicity in differentiated human SH-SY5Y neuroblastoma cells. Neurosci Lett 405, 46-51 https://doi.org/10.1016/j.neulet.2006.06.061
  59. Verhaar R, Jongenelen CA, Gerard M et al (2011) Blockade of enzyme activity inhibits tissue transglutaminasemediated transamidation of alpha-synuclein in a cellular model of Parkinson's disease. Neurochem Int 58, 785-793 https://doi.org/10.1016/j.neuint.2011.03.004
  60. Junn E, Ronchetti RD, Quezado MM, Kim SY and Mouradian MM (2003) Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci U S A 100, 2047-2052 https://doi.org/10.1073/pnas.0438021100
  61. Schmid AW, Chiappe D, Pignat V et al (2009) Dissecting the mechanisms of tissue transglutaminase-induced crosslinking of alpha-synuclein: implications for the pathogenesis of Parkinson disease. J Biol Chem 284, 13128-13142 https://doi.org/10.1074/jbc.M809067200
  62. Sato H, Arawaka S, Hara S et al (2011) Authentically phosphorylated alpha-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease. J Neurosci 31, 16884-16894 https://doi.org/10.1523/JNEUROSCI.3967-11.2011
  63. Min B, Kwon YC, Choe KM and Chung KC (2015) PINK1 phosphorylates transglutaminase 2 and blocks its proteasomal degradation. J Neurosci Res 93, 722-735 https://doi.org/10.1002/jnr.23535
  64. Verhaar R, Drukarch B, Bol JG, Jongenelen CA, Musters RJ and Wilhelmus MM (2012) Increase in endoplasmic reticulum-associated tissue transglutaminase and enzymatic activation in a cellular model of Parkinson's disease. Neurobiol Dis 45, 839-850 https://doi.org/10.1016/j.nbd.2011.10.012
  65. Wilhelmus MM, Verhaar R, Andringa G et al (2011) Presence of tissue transglutaminase in granular endoplasmic reticulum is characteristic of melanized neurons in Parkinson's disease brain. Brain Pathol 21, 130-139 https://doi.org/10.1111/j.1750-3639.2010.00429.x
  66. Gibrat C, Bousquet M, Saint-Pierre M et al (2010) Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor. Prog Neuropsychopharmacol Biol Psychiatry 34, 193-203 https://doi.org/10.1016/j.pnpbp.2009.11.005
  67. Tremblay ME, Saint-Pierre M, Bourhis E, Levesque D, Rouillard C and Cicchetti F (2006) Neuroprotective effects of cystamine in aged parkinsonian mice. Neurobiol Aging 27, 862-870 https://doi.org/10.1016/j.neurobiolaging.2005.04.004
  68. Davies SW, Turmaine M, Cozens BA et al (1997) Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537-548 https://doi.org/10.1016/S0092-8674(00)80513-9
  69. Zainelli GM, Ross CA, Troncoso JC, Fitzgerald JK and Mumna NA (2004) Calmodulin regulates transglutaminase 2 cross-linking of huntingtin. J Neurosci 24, 1954-1961 https://doi.org/10.1523/JNEUROSCI.4424-03.2004
  70. Mastroberardino PG, Iannicola C, Nardacci R et al (2002) 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease. Cell Death Differ 9, 873-880 https://doi.org/10.1038/sj.cdd.4401093
  71. Bailey CD and Johnson GV (2005) Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregateindependent mechanisms. J Neurochem 92, 83-92 https://doi.org/10.1111/j.1471-4159.2004.02839.x
  72. Sun L, Xu S, Zhou M, Wang C, Wu Y and Chan P (2010) Effects of cysteamine on MPTP-induced dopaminergic neurodegeneration in mice. Brain Res 1335, 74-82 https://doi.org/10.1016/j.brainres.2010.03.079
  73. Sung K, Kamiya N, Kawata N, Kamiya S and Goto M (2010) Functional glass surface displaying a glutamyl donor substrate for transglutaminase-mediated protein immobilization. Biotechnol J 5, 456-462 https://doi.org/10.1002/biot.200900302
  74. Karpuj MV, Becher MW, Springer JE et al (2002) Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 8, 143-149 https://doi.org/10.1038/nm0202-143
  75. Dedeoglu A, Kubilus JK, Jeitner TM et al (2002) Therapeutic effects of cystamine in a murine model of Huntington's disease. J Neurosci 22, 8942-8950 https://doi.org/10.1523/JNEUROSCI.22-20-08942.2002
  76. Wang X, Sarkar A, Cicchetti F et al (2005) Cerebral PET imaging and histological evidence of transglutaminase inhibitor cystamine induced neuroprotection in transgenic R6/2 mouse model of Huntington's disease. J Neurol Sci 231, 57-66 https://doi.org/10.1016/j.jns.2004.12.011
  77. Case A, Ni J, Yeh LA and Stein RL (2005) Development of a mechanism-based assay for tissue transglutaminase--results of a high-throughput screen and discovery of inhibitors. Anal Biochem 338, 237-244 https://doi.org/10.1016/j.ab.2004.09.047

Cited by

  1. Concurrent detection of lysosome and tissue transglutaminase activation in relation to cell cycle position during apoptosis induced by different anticancer drugs pp.15524922, 2018, https://doi.org/10.1002/cyto.a.23652
  2. Spotlight on the transglutaminase 2 gene: a focus on genomic and transcriptional aspects vol.475, pp.9, 2018, https://doi.org/10.1042/BCJ20170601
  3. vol.294, pp.2, 2018, https://doi.org/10.1074/jbc.RA118.005489
  4. The Role of Tissue Transglutaminase in Cancer Cell Initiation, Survival and Progression vol.7, pp.2, 2019, https://doi.org/10.3390/medsci7020019